Zhou CY, Ren XY, Li HH, Pan XM, Lan X, Duan D. Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature. World J Clin Oncol 2026; 17(5): 119615 [DOI: 10.5306/wjco.v17.i5.119615]
Corresponding Author of This Article
Dong Duan, Department of Nuclear Medicine, Chongqing General Hospital, No. 118 Xingguang Avenue, Liangjiang New Area, Chongqing 400700, China. duandong26@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
May 24, 2026 (publication date) through May 23, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zhou CY, Ren XY, Li HH, Pan XM, Lan X, Duan D. Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature. World J Clin Oncol 2026; 17(5): 119615 [DOI: 10.5306/wjco.v17.i5.119615]
World J Clin Oncol. May 24, 2026; 17(5): 119615 Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.119615
Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature
Chun-Yan Zhou, Xin-Yi Ren, Huan-Huan Li, Xiao-Mei Pan, Xin Lan, Dong Duan, Department of Nuclear Medicine, Chongqing General Hospital, Chongqing 400700, China
Author contributions: Zhou CY drafted the manuscript; Ren XY, Li HH, Pan XM, and Lan X collected the data; Duan D reviewed and edited the final manuscript; and all authors read and approved the final manuscript.
AI contribution statement: DeepL was used to assist with translation checking, and Grammarly was used for language polishing to improve grammar and readability. All content was subsequently reviewed and revised by the authors to ensure accuracy and integrity.
Supported by Natural Science Foundation of Chongqing, China, No. CSTB2023NSCQ-MSX0678.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Dong Duan, Department of Nuclear Medicine, Chongqing General Hospital, No. 118 Xingguang Avenue, Liangjiang New Area, Chongqing 400700, China. duandong26@163.com
Received: February 2, 2026 Revised: March 6, 2026 Accepted: April 1, 2026 Published online: May 24, 2026 Processing time: 108 Days and 3.1 Hours
Core Tip
Core Tip: Effective salvage treatments for radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) following sorafenib failure remain severely limited. This case report presents an innovative combination and maintenance strategy. By employing anlotinib plus albumin-bound paclitaxel as induction therapy to potentially promote vascular normalization and enhance cytotoxic drug delivery, followed by anlotinib maintenance, a patient with metastatic RAIR-DTC achieved a confirmed partial response. With manageable toxicity and progression-free survival exceeding 38 months, this case suggests that the anlotinib-based regimen may provide durable disease control and warrants further prospective evaluation in patients who have exhausted first-line multikinase inhibitors.
